Quantification of in vivo binding of [3H]RX 821002 in rat brain: evaluation as a radioligand for central alpha 2-adrenoceptors.

Abstract

On the basis of its established in vitro characteristics, [3H]RX 821002 was evaluated in rats as an in vivo radioligand for central alpha 2-adrenoceptors. Estimates for in vivo binding potential, obtained by compartmental analyses of time-radioactivity data, ranged between 1.9 for hypothalamus and 0.2 for cerebellum, with a regional distribution in brain which was similar to that observed in vitro. Selectivity and specificity of the signal were checked by predosing with either the alpha 2-antagonists, idazoxan or yohimbine, the alpha 2-agonist, clonidine, or the alpha 1-antagonist, prazosin. Pretreatment of the rats with the selective neurotoxin, DSP-4, had no significant effect on [3H]RX 821002 binding, suggesting that the majority of labelled sites were situated post-junctionally. The studies indicate that [3H]RX 821002 can be used experimentally as an in vivo marker for central alpha 2-adrenoceptors. The size and rate of expression of the specific signal encourage the development and assessment of [11C]RX 821002 for clinical PET studies.

Statistics

050100150'01'03'05'07'09'11'13'15'17
Citations per Year

101 Citations

Semantic Scholar estimates that this publication has 101 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hume1992QuantificationOI, title={Quantification of in vivo binding of [3H]RX 821002 in rat brain: evaluation as a radioligand for central alpha 2-adrenoceptors.}, author={S. P. Hume and Adriaan A. Lammertsma and Jolanta Opacka-Juffry and R. G. Ahier and Ralph Myers and Jill E. Cremer and Alan L. Hudson and David J. Nutt and Victor W. Pike}, journal={International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology}, year={1992}, volume={19 8}, pages={841-9} }